Effectiveness and complications of 153Sm-EDTMP in palliative treatment of diffuse skeletal metastases

Document Type : Original Article


1 Research Center for Nuclear Medicine, Tehran University of Medical Sciences, Tehran, Iran

2 Department of Radiation Oncology, Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Iran

3 Radiation Oncology Department, Cancer Research Center, Shohada-e-Tajrish Hospital, Shaheed Beheshti University of Medical Sciences, Tehran, Iran


Introduction: The aim of the present study was to evaluate the efficacy and safety profile of bone palliative therapy following administration of 153Sm-EDTMP in patients with intractable metastatic bone pain.
Methods: Sixteen patients (9 male, 7 female) aged 29-80 years (57.3±16.7 years) with severe metastasis-related bone pain resistant to analgesic medications were enrolled in the study. All patients having multiple bone metastases, positive bone scans, and estimated life expectancy of more than 2-3 months were entered the study. All patients received intravenous injection of 1.5 mCi (56 MBq)/kg of 153Sm-EDTMP. Four subscales for the intensity of pain were recorded: one as the present pain score (PPS) and the other three as maximum pain score (Max PS), minimum pain score (Min PS) and average pain score (APS) over the last 24 hours. Also the mean value of these 4 subscales was calculated as the mean total pain score (MTPS). The pain mental interference (PMI) was also assessed in 9 separate.
Results: Seven patients with breast cancer (43.75%), seven with prostate cancer (43.75%), one with papillary thyroid carcinoma (6.25%) and one with malignant paraganglioma (6.25%) were included in the study. A significant response to therapy, i.e. 2-point reduction in pain score and/or remarkable reduction (³25%) in the equivalent narcotic dose, was observed in 11 out of 16 patients (68.7%) by the 2nd week and in 12 patients (75%) by the 8th week. Regarding the palliative response to treatment and equivalent narcotic dose reduction, no significant difference between two major types of underlying malignancies (breast and prostate cancer) was found. There was no significant difference regarding response to therapy between two genders and among different age groups. The severity of bone marrow suppression was graded ≤2 in all patients.

Conclusion: Response to palliative treatment with 153Sm-EDTMP in prostate and breast cancers is the same at the rate of 75% at the end of 8th week post-infusion. Hematologic toxicity is mild to moderate and no life-threatening side effect is observed.


Main Subjects

Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005 Jun;6(6):392-400.
Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: a systematic review. J Clin Oncol. 2007 Apr 10;25(11):1423-36.
Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol. 2007 Jul;19(4):308-14.
Haddad P, Wong RKS, Pond GR, Soban F, Williams D, McLean M, Levin W, Bezjak A. Factors influencing the use of single vs multiple fractions of palliative radiotherapy for bone metastase: a 5-year review. Clin Oncol (R Coll Radiol). 2005 Sep;17(6):430-4.
Baczyk M, Czepczynski R, milecki P, Pisarek M, Oleksa R, Sowinski J. 89Sr versus 153Sm-EDTMP: comparison of treatment efficacy of painful bone metastase in prostate and breast carcinoma. Nucl Med Commun. 2007 Apr;28(4):245-50.
Liepe K, Kotzerke J. A comparative study of 188Re-HEDP, 186Re-HEDP, 153Sm-EDTMP and 89Sr in the treatment of painful skeletal metastases. Nucl Med Commun. 2007 Aug;28(8):623-30.
Lewington VJ. Targeted radionuclide therapy for bone metastases. Eur J Nucl Med. 1993 Jan;20(1):66-74.
Volkert WA, Keutsch EA. Bone-seaking radiopharmaceuticals in cancer therapy. Advances Metals Med. 1991;1:115-53.
Holmes Ra. [153Sm] EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med. 1992 Jan;22(1):41-5.
Dickie GJ, Macfarlane D. Strontium and samarium therapy for bone metastases from prostate carcinoma. Australas Radiol. 1999 Nov;43(4):476-9.
Resche I, Chatal JF, Pecking A, Ell P, Duchesne G, Rubens R, Fogelman I, Houston S, Fauser A, Fischer M, Wilkins D. A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997 Sep;33(10):1583-91.
Serafini AN, Houston SJ, Resche I, Quick DP, Grund FM, Ell PJ, Bertrand A, Ahmann FR, Orihuela E, Reid RH, Lerski RA, Collier BD, McKillop JH, Purnell GL, Pecking AP, Thomas FD, Harrison KA. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol. 1998 Apr;16(4):1574-81.
Mc Evans AJ. Palliative therapy with bone seeking radiopharmaceuticals. Cancer Biother Radiopharm. 1998 Dec;13(6):413-26.
Baumann G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastases: a systematic review. Radiother Oncol. 2005 Jun;75(3):258-70.
Liepe K, Runge R, Kotzerke J. The benefit of bone-seeking radiopharmaceuticals in the treatment of metastatic bone pain. J Cancer Res Clin Oncol. 2005 Jan;131(1):60-6.
Lass P. Radionuclide treatment of bone metastases – current concepts and trends. Nucl Med Rev Cent East Eur. 2001;4(1):1-3.
Royal Australian College of General Practitioners. Medical care of older persons in residential aged care facilities. 4th ed. The Royal Australian College of General Practitioners, 2006.
Bishayee A, Rao DV, Srivastava SC,Bouchet LG, Bolch WE, Howell RW. Marrow sparing effects of 117mSn(4+) diethylenetriaminepentaaceticacid for radionuclide therapy of bone cancer. J Nucl Med. 2000 Dec;41(12):2043-50.
Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NS, Russell JM, Yardley J. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol. 1994 Apr;31(1):33-40.
Pons F, Herranz R, Garcia A, Vidal-Sicart S, Conill C, Grau JJ, Alcover J, Fuster D, Setoain J. Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer. Eur J Nucl Med. 1997 Oct;24(10):1210-4.
Alberts AS, Smit BJ, Louw WK, van Rensburg AJ, van Beek A, Kritzinger V, Nel JS. Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone. Radiother Oncol. 1997 May;43(2):175-9.
Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, Macleod PM, Zivanovic MA. Strontium-89 chloride for pain palliation in prostatic skeletal malignancy. Br. J. Radiol. (1991) 64: 816–822.
Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004 May;63(5):940-5.
Han SH, De Klerk JMH, Zonnenberg BA, Tan S, van Rijk PP. Efficacy of Re-186 etidronate palliative radionuclide therapy for painful bone metastases. Q J Nucl Med. 2001;45:84–90.
Lee CK, Aeppli DM, Unger J, Boudreau RJ, Levitt SH. Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. Am J Clin Oncol. 1996 Apr;19(2):102-7.
Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: A phase I/II trial. J Nucl Med. 1993 Nov;34(11):1839-44.
Enrique O, Zhonyun P, Prma EP, Pusuwan P,  Ricobona G, Tian JH, Obaldo J,Padhy AK. Efficiency and toxicity of Sm-153 EDTMP in the palliative treatment of painful bone metastases. World J Nucl Med. 2002;1:21–7.
Ahonen A, Joensuu H, Hiltunen J, Hannelin M, Heikkilä J, Jakobsson M, Jurvelin J, Kairemo K, Kumpulainen E, Kulmala J. Samarium-153-EDTMP in bone metastases. J Nucl Biol Med. 1994 Dec;38(4 Suppl 1):123-7.
Ricci S, Boni G, Pastina I, Genovesi D, Cianci C, Chiacchio S, Orlandini C, Grosso M, Alsharif A, Chioni A, Di Donato S, Francesca F, Selli C, Rubello D, Mariani G. Clinical benefit of bone-targeted radiometabolic therapy with Sm-EDTMP combined with chemotherapy in patients with metastatic hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging. 2007 Jul;34(7):1023-30.
Dolezal J. Efficacy and toxicity of 153samarium-EDTMP in painful breast cancer bone metastases. Onkologie. 2009 Feb;32(1-2):35-9.
Feng JY, Wu CQ, Zhang P, Wang SJ, Zheng XH. Efficacy of 153Sm-EDTMP in the treatment of prostate cancer with bone metastasis. Zhonghua Nan Ke Xue. 2012 Nov;18(11):982-5.
Anderson P, Nuñez R. Samarium lexidronam (153Sm-EDTMP): skeletal radiation for osteoblastic bone metastases and osteosarcoma. Expert Rev Anticancer Ther. 2007 Nov;7(11):1517-27.
Turner JH, Martindale AA, Sorby P, Hetherington EL, Fleay RF, Hoffman RF, Claringbold PG. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med. 1989;15(12):784-95.
Sinzinger H, Weiss K, Hiltunen J. Background, reasons and benefits using the vienna protocol for the treatment of painful bone recurrences with 153Samarium-EDTMP. Anticancer Res. 2009 Aug;29(8):3393-5.
Vigna L, Matheoud R, Ridone S, Arginelli D, Della Monica P, Rudoni M, Inglese E, Brambilla M. Characterization of the [(153)Sm]Sm-EDTMP pharmacokinetics and estimation of radiation absorbed dose on an individual basis. Phys Med. 2011 Jul;27(3):144-52.
Berger M, Grignani G, Giostra A, Ferrari S, Ferraresi V, Tamburini A, Cefalo G, Carnevale-Schianca F, Vassallo E, Picci P, Pagano M, Aglietta M, Pellerito RE, Fagioli F. 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol. 2012 Jul;23(7):1899-905.